David Horrobin Bibliography
2000
832
Bennett, C.N. and Horrobin, D.F.
Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update [review]
Prostaglandins Leukot Essent Fatty Acids 2000; 63(1): 47-59.
(Abstract)


833
Ho, L.; Pasinetti, G.M.; Horrocks, L.A.; Faroqui, A.A.; Horrobin, D.F.; Peet, M.; Manev, H.
Eicosanoid pathways in psychiatric disorders (Abstract)
Biol Psychiatry 2000; 47: 114S.


834
Horrobin, D.F.
Essential fatty acid metabolism and its modification in atopic eczema [review]
Am J Clin Nutr 2000; 71(1 Supp): 367S-72S.
(Full text)  (Abstract)


835
Horrobin, D.F.
Why is speculation so awful? [letter]
Br Med J 2000; 321(7260): 571-2.
(Full text)  

836
Horrobin, D.F.
Photodynamic injury from Foscan [letter]
Br Med J eletters: http://bmj.com/cgi/eletters/321/7252/53/a#11234 2000.
(Full text)  

837
Horrobin, D.F.
A revolution in drug discovery [letter]
Br Med J eletters: http://bmj.com/cgi/eletters/321/7261/581#9991 2000.
(Full text)  

838
Horrobin, D.F.
Low frequency EMF, visible light, melatonin and cancer [Conference report]
In: Erren TC, Piekarski C. (Eds.) Low frequency EMF, visible light, melatonin and cancer - International symposium May 4-5, 2000 University of Cologne. Zbl Arbeitsmed 2000; 50: 298-314.
(Full text)  

839
Horrobin, D.F.
Essential fatty acids and diabetic neuropathy
Inform 2000; 11(5).


840
Horrobin, D.F.
The other side of Scotia's drug policy
Investor's Chronicle 2000; 134: 120.


841
Horrobin, D.F.
Innovation in the pharmaceutical industry
J R Soc Med 2000; 93(7): 341-5.
(Full text)  

842
Horrobin, D.F.
The LAX-101 research project in Huntington's disease
Presentation to: Huntingdon Disease Association Conference, Sheffield, UK. 21 October 2000.
(Full text)  

843
Horrobin, D.F.
Commentary on the workshop statement: are we really sure that arachidonic acid and linoleic acid are bad things?
Prostaglandins Leukot Essent Fatty Acids 2000; 63(3): 145-7.


844
Horrobin, D.F.
Phospholipid metabolism and perinatal events whiche lead to increased risk of schizophrenia
Schizophrenia Res 2000; 41: 250.


845
Horrobin, D.F.
Interactions between cannabinoids and phospholipid metabolism in schizophrenia
Schizophrenia Res 2000; 41: 250.


846
Horrobin, D.F.
Phospholipid metabolism and pregnancy-related events which enhance risk of schizophrenia
Schizophrenia Res 2000; 41: 251.


847
Horrobin, D.F.
Phospholipases as candidate genes in schizophrenia
Schizophrenia Res 2000; 41: 98.


848
Horrobin, D.F. and Bennett, C.N.
Fatty acid coenzyme A ligases as candidate genes in schizophrenia
Schizophrenia Res 2000; 41: 99.


849
MacDonald, D.J.; Glen, A.C.A.; Boyle, R.M.; Glen, A.I.M.; Ward, P.; Horrobin, D.F.
An ELISA method for type IV cPLA2 in RBC: a potential marker for schizophrenia
Schizophrenia Res 2000; 41: 259.


850
MacDonell, L.E.; Skinner, F.K.; Ward, P.E.; Glen, A.I.; Glen, A.C.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F.
Increased levels of cytosolic phospholipase A2 in dyslexics
Prostaglandins Leukot Essent Fatty Acids 2000; 63(1): 37-9.
(Abstract)


851
MacDonnell, L.E.F.; Skinner, F.K.; Ward, P.E.; Glen, A.I.M.; Glen, A.C.A.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F.
Type IV cPLA2 in red blood cells: evidence for differences between two subgroups on dyslexic-type adults and controls
Schizophrenia Res 2000; 41: 258.


852
Martin, D.S.D.; Towey, M.; Horrobin, D.F.; Lynch, M.A.
A diet enriched with alpha-lipoic acid reverses the age-related compromise in antioxidant defences in rat cortical tissue
Nutr Neurosci 2000; 3: 193-206.


853
Peet, M.; Glen, A.I.M.; Ward, P.; Rowlands, P.; Puri, B.K.; Murray, R.; de Wet, C.; Kendall, K.; Abed, R.; Inch, H.; Driscoll, P.; Lloyd, G.; Barber, M.; Hay, A.; McGregor, A.; Hellewell, J.; Mackenzie, A.; Glen, F.; Horrobin, D.F.
Effects of eicosapentaenoic acid in schizophrenia: a placebo-controlled trial (Abstract)
Presented at: 10th Winter Workshop on Schizophrenia, Davos, Switzerland, February 2000.


854
Peet, M.; Horrobin, D.F.; Glen, A.I.M.; Ward, P.; Rowlands, P.; Puri, B.K.; Murray, R.; de Wet, C.; Kendall, K.; Abed, R.; Inch, H.; Driscoll, P.; Lloyd, G.; Barber, M.; Hay, A.; McGregor, A.; Hellewell, J.; Mackenzie, A.; Glen, F.
Eicosapentaenoic acid in the management of treatment-unresponsive schizophrenia (Abstract)
Presented at: Br Assoc Psychopharmacol Summer Meeting, 16-19 July, Cambridge, UK. 2000: 43.


855
Puri, B.K.; Richardson, A.J.; Easton, T.; Saeed, N.; Counsell, S.J.; Hajnal, J.V.; Bydder, G.M.; Horrobin, D.F.
Reduced neuronal membrane phospholipid turnover and normalization of blood fatty acids associated with symptom remission in a patient with schizophrenia treated solely with eicosapentaenoic acid
Schizophr Res 2000; 41: 243.


856
Puri, B.K.; Richardson, A.J.; Horrobin, D.F.; Easton, T.; Saeed, N.; Oatridge, A.; Hajnal, J.V.; Bydder, G.M.
Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes
Int J Clin Pract 2000; 54(1): 57-63.
(Abstract)


857
Ward, P.E.; Glen, A.I.M.; Glen, A.C.A.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F.
Phospholipids, niacin skin test and type IV cPLA2 in schizophrenia
Schizophr Res 2000; 41: 244.


858
Ward, P.E.; Glen, A.I.M.; MacDonald, D.J.; Boyle, R.M.; Horrobin, D.F.
Type IV cPLA2 in red blood cells: a preliminary clinical evaluation of its use as a marker for schizophrenia
Schizophr Res 2000; 41: 259.


859
Yao, J.K.; Reddy, R.D.; Pettegrew, J.W.; van Kammen, D.P.; Horrobin, D.F.; Mahadik, S.P.
Membrane deficits in schizophrenia (Abstract)
Biol Psychiatry 2000; 47: 58S.




All copyrights acknowledged

© Peter Lapinskas 1999-2012 Email Peter Lapinskas Last updated: 3 July 2012

Home      Services      Background      Publications      Resources      Contact